Novartis AG stock (CH0012005267): Zacks cuts Q2 2026 EPS forecast

Zacks Research lowered its Q2 2026 EPS estimate for Novartis AG to $2.24 from $2.37, while trimming FY2026 to $8.75. This follows the company's Q1 2026 earnings miss of $1.99 versus $2.11 expected, despite revenue beating at $13.52 billion.

Zacks Research issued revised earnings estimates for Novartis AG on May 8, 2026, cutting its Q2 2026 EPS forecast to $2.24 per share from a previous $2.37, according to MarketBeat as of May 11, 2026. The firm also reduced its full-year 2026 EPS projection to $8.75, below the consensus of $8.85. This adjustment comes after Novartis reported Q1 2026 results on April 27, 2026, with EPS of $1.99 missing the $2.11 estimate, though revenue reached $13.52 billion against $13.44 billion expected, per MarketBeat as of May 11, 2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis AG
• Sector/industry: Pharmaceuticals
• Headquarters/country: Basel, Switzerland
• Core markets: US, Europe, Asia
• Key revenue drivers: Innovative medicines in cardio, oncology
• Home exchange/listing venue: NYSE (NVS)
• Trading currency: USD

Novartis AG: core business model

Novartis AG focuses on developing and marketing innovative medicines, emphasizing areas like cardiovascular, oncology, immunology, and neuroscience. The company operates as a pure-play innovator following strategic divestments, including its recent sale of a stake in its Indian subsidiary for approximately Rs 1,446 crore. This shift allows Novartis to concentrate resources on high-value R&D, particularly in its India hub for research and development.

Main revenue and product drivers for Novartis AG

Key products such as Entresto for heart failure and oncology treatments drive Novartis AG's revenue, supported by strong patent protections. In Q1 2026, revenue totaled $13.52 billion, up slightly from prior periods despite the EPS miss, reflecting resilient demand in core markets including the US, where it holds significant share in pharmaceuticals.

Industry trends and competitive position

The pharmaceutical sector faces patent cliffs and pricing pressures, yet Novartis AG maintains a competitive edge through its innovative pipeline and focus on high-margin therapies. Institutional investors like NewEdge Wealth increased stakes by 3.9% in Q4 2025 to $69.67 million, signaling confidence amid Hold consensus ratings.

Why Novartis AG matters for US investors

Listed on NYSE as NVS, Novartis AG offers US investors exposure to global pharma leadership with substantial US market revenue. Its products address critical healthcare needs, aligning with US demographic trends in aging populations and chronic diseases.

Conclusion

Novartis AG navigates earnings challenges with downward analyst revisions from Zacks Research, yet demonstrates revenue strength and strategic focus on innovation. Institutional interest persists, while the stock holds a Hold rating with a $141.20 average target. Investors monitor upcoming quarters for pipeline progress and profitability recovery.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.